20 results about "Secreting cell" patented technology

The present disclosure relates to a transplantable cell therapy product composition for diabetes mellitus that contains an aggregate of insulin-secreting cells derived from stem cells. In the present disclosure, an NF microwell array membrane was fabricated by applying a molding process to an electrospun, permeable, biodegradable polycaprolactone (PCL) NF membrane and thus allows gases and soluble factors to permeate therethrough. The NF microwell of the present disclosure could provide more nutrients to the iPSC aggregates than conventional impermeable PDMS microwells, thus enhancing survival and differentiation capabilities of the cells. Additionally, the NF membrane was attached singly to the subcutaneous tissue and to the surface of organs such as liver and peritoneum without the need for a fixing material or separate sutures and was integrated with surrounding tissues, resulting in higher insulin secretion than PDMS microwells. Therefore, the present disclosure can be effectively utilized as a composition for the prevention or treatment of diabetes.

Methods and compositions for generating B lineage cells, such as plasmablasts, plasma cells, and protein producing or protein secreting B cells are disclosed. The methods can involve stage-specific differentiation from stem cells or stem cell-derived hematopoietic progenitor cells through one or more intermediates to B lineage cells, such as plasmablasts, plasma cells, and protein producing or protein secreting B cells.

Disclosed are methods and compositions for generating B lineage cells, such as plasmablasts, plasma cells, and protein-producing or protein-secreting B cells. The methods may relate to stage-specific differentiation from stem cells or stem-cell derived hematopoietic progenitors through one or more intermediates to B lineage cells, such as plasmablasts, plasma cells, and protein-producing or protein-secreting B cells.

Described herein is an engineered viral subunit vaccine encoding ASFV capsid proteins (e.g., P72 and Penton) for use in pigs. The vaccine with either P72 or Penton tested in mice elicited significantly higher levels of antigen-specific IgM and IgG, increased frequency of antibody-secreting cells in the bone marrow, and higher quality germinal centers in the spleens of immunized mice. Enhanced T cell responses were also observed, with higher levels of IFN-γ and TNF-α in splenocytes. Immunogenicity assessments in pigs further supported these findings, with both MB-P72 and MB-PN180Q inducing robust B cell and T cell responses. These findings show that expression of capsid proteins P72 and Penton in membrane-bound forms via mRNA preserves their native multimeric structure and enhances their immunogenicity and provides a basis for an effective ASFV vaccine.

The present application belongs to the field of biomedicine, and relates to an inducer for inducing mesenchymal stem cells to differentiate into estradiol-secreting cells. The inducer for inducing mesenchymal stem cells to differentiate into estradiol-secreting cells is based on a human mesenchymal stem cell serum-free culture medium, and is composed of the following components in a mass concentration ratio: bone morphogenetic protein-4 20-60 mg / L, bone morphogenetic protein-7 20-60 mg / L, tretinoin 2-8 mg / L, resveratrol 2-8 mg / L, icariin 2-8 mg / L, benzamide 2-8 ug / L, chloroplatinic acid hexahydrate 2-8 ug / L, ethanolamine 2-8 ug / L, erythropoietin 2-10 ug / L, and vascular endothelial growth factor 2-10 ug / L. The inducer for inducing mesenchymal stem cells to differentiate into estradiol-secreting cells has high induction efficiency.

The invention discloses an influenza B virus T3 peptide fragment capable of inducing cellular immune response and application of the influenza B virus T3 peptide fragment, and belongs to the technical field of immunotherapy and immunodetection. According to the invention, detection is carried out through ELISpot, and the immunogenicity of the long peptide (SEQ ID NO.1, named as T3) is verified in 21 volunteers. The result shows that the T3 is detected to be positive in four persons, and the positive rate is 19.05%; the IFN-gamma secretory cells of the human PBMCs are detected through ELISpot, and the immune response induced by the T3 in people can reach up to 2870 SFC / 106 PBMC. Therefore, the polypeptide has good immunogenicity and crowd universality, can be used as a specific detection peptide for monitoring the cellular immune level, can effectively activate the T cell immune response of the crowd, and has the potential of being used as a candidate vaccine epitope peptide to be applied to novel vaccine design.

The present disclosure is directed to a method of producing human gastric insulin-secreting (GINS) cells and human gastric insulin-secreting (GINS) organoids. The present disclosure provides a population of human gastric insulin-secreting (GINS) cells and a preparation of human gastric insulin-secreting (GINS) organoids, which are glucose-responsive and insulin-secreting. The present disclosure also provides methods of controlling glycemia in a human subject by transplanting to the human subject the population of human GINS cells or the preparation of human GINS organoids.

The invention discloses a stomach body three-dimensional organoid culture medium as well as a preparation method and a culture method thereof, and belongs to the technical field of organoid culture. The stomach body three-dimensional organoid culture medium comprises a basic culture medium and a stomach body organoid growth supplement, the stomach body organoid growth supplement comprises a Wnt signaling pathway agonist, an FGF (Fibroblast Growth Factor) family member, a TGF-beta signaling pathway inhibitor, hyaluronic acid and retinoic acid. The invention further discloses a preparation method of the gastric body three-dimensional organoid culture medium and a gastric body three-dimensional organoid culture method. The method can solve the problems that the existing organoid culture technology is difficult to effectively maintain and amplify the stomach organoid with the functional oxyntocytes, and the existing organoid culture technology has unstable pedigree and incomplete structure.

An object of the present invention is to provide an approach of removing non-endocrine unintended cells coexisting with insulin-secreting cells obtained by the differentiation. The present invention relates to a method for producing an insulin-producing cell population, comprising the step of treating an insulin-producing cell population obtained by the differentiation from pluripotent stem cells with a PLK inhibitor.

The present invention relates to a method for detecting single cell lactic acid secretion, and specifically provides a method for detecting cell lactic acid secretion, comprising: 1) incubating a fluorescent probe and cells in separate partitions, and 2) detecting the fluorescent signal, wherein the fluorescent signal of the partition where the lactic acid secreting cell is located is weakened. The method of the present application achieves accurate detection of cell lactic acid secretion.

The invention relates to the technical field of regenerative medicine and cell therapy, in particular to a culture medium for inducing mesenchymal cells to differentiate into insulin-secreting cells and application of the culture medium. By accurately regulating and controlling the oxidation-reduction state of NAD < + > / NADH in cells, the composition proportion of exogenous fatty acid, the dynamic supply concentration of glucose and the anti-oxidative stress level, the differentiation efficiency is remarkably improved, the induction period is shortened, and the method is suitable for industrial production on the premise of not depending on recombinant protein induction factors such as Activin A and Wnt3a. And a mature beta-like cell with stable glucose stimulus dependent insulin secretion (GSIS) capability is obtained. The kit is especially suitable for human adipose tissue-derived mesenchymal stem cells, and can be used as an independent kit product for preclinical research and drug screening of diabetes cell replacement therapy.

The invention relates to the technical field of regenerative medicine and cell therapy, in particular to a method for inducing mesenchymal stem cells to differentiate into insulin-secreting cells and application of the method. According to the method, a culture system is regulated and controlled by stages, the glucose concentration is respectively regulated in different induction stages, an NAD + precursor substance, a fatty acid composition and an antioxidant factor are added, and a three-dimensional microcarrier culture mode is combined, so that the cell metabolism state, the oxidation-reduction balance and the space structure are dynamically regulated and controlled. Under the condition of not depending on recombinant protein inducing factors such as Activin A and Wnt3a, the efficient directional differentiation of the mesenchymal stem cells to the insulin-secreting cells is realized. By adopting the method disclosed by the invention, the differentiation efficiency can be improved, the induction period can be shortened, the mature beta-like cells with a stable glucose stimulation dependent insulin secretion function can be obtained, and the method is suitable for induced differentiation and related research application of the human adipose-derived mesenchymal stem cells.

The invention discloses an influenza B virus T2 peptide fragment capable of inducing cellular immune response and application of the influenza B virus T2 peptide fragment, and belongs to the technical field of immunotherapy and immunodetection. Verification is carried out through ELISpot, T2 is detected to be positive in six persons, the positive rate is 28.57%, S-T2 is detected to be positive in four persons, and the positive rate is 19.05%; the IFN-gamma secretory cells of the human PBMCs are detected through ELISpot, the highest immune response induced by T2 in the HLA-A2 population can reach 890 SFC / 106 PBMC, and the highest immune response induced by S-T2 in the HLA-A2 population can reach 650 SFC / 106 PBMC. Therefore, T2 and S-T2 can stably induce human T cells to generate immune response, can be used for monitoring the cellular immune level, can effectively activate the T cell immune response of people, and has the potential of being used as candidate vaccine epitope peptide to be applied to novel vaccine design.

The application discloses application of MST1 interfering RNA in promoting in-vitro differentiation of ESCs into insulin-secreting cells, and belongs to the technical field of biotechnology. In the process of in-vitro directional differentiation of rat ESCs into beta cells, the application infects by using an MST1 shRNA lentivirus vector, and indexes are detected and functions are determined by using cell biology and molecular biology methods, and it is found for the first time that the efficiency of inducing ESCs to differentiate into beta cell-like cells can be improved by reducing the expression of MST1. Meanwhile, how MST1 realizes the regulation of beta cell maturation by means of PDX1 in the process of directional differentiation of rat ESCs into beta cells is described, the reason affecting in-vitro maturation of beta cells is discussed, and thus the system of directional differentiation of ESCs into mature beta cells is optimized, which has important significance for obtaining beta cells with normal insulin secretion function in-vitro.

The present disclosure belongs to the field of biological medicines, and relates to an inducer for inducing differentiation of mesenchymal stem cells into estradiol-secreting cells. The inducer for inducing differentiation of mesenchymal stem cells into estradiol-secreting cells uses human mesenchymal stem cell serum-free culture medium as a substrate and comprises the following components in mass concentration ratios: 20-60 mg / L of bone morphogenetic protein-4, 20-60 mg / L of bone morphogenetic protein-7, 2-8 mg / L of retinoic acid, 2-8 mg / L of resveratrol, 2-8 mg / L of icariin, 2-8 μg / L of benzamide, 2-8 μg / L of chloroplatinic acid hexahydrate, 2-8 μg / L of ethanolamine, 2-10 μg / L of erythropoietin and 2-10 μg / L of vascular endothelial growth factor. The inducer for inducing differentiation of mesenchymal stem cells into estradiol-secreting cells provided by the present disclosure has a high induction efficiency.

The invention discloses application of temperature-sensitive hydroxypropyl chitin hydrogel in preparation of a medicine for treating intervertebral disc degeneration, and belongs to the technical field of biological medicine. The temperature-sensitive hydroxypropyl chitin hydrogel has good biocompatibility and temperature sensitivity, is liquid in a low-temperature state, quickly forms transparent hydrogel after entering a human body, and can seal a damaged fibrous ring and prevent medicine leakage. The fibroblast has the functions of secreting extracellular matrix and inhibiting inflammation, and can maintain the height and stability of the intervertebral disc and relieve clinical symptoms. The combination of the temperature-sensitive hydroxypropyl chitin hydrogel and the fibroblast can promote the fibroblast to secrete an extracellular matrix, provide a stronger biomechanical function, give full play to the curative effect in a patient with a broken fibrous ring, and fill the gap of leakage type intervertebral disc cell therapy.

The invention discloses an influenza B virus T1 peptide fragment capable of inducing cellular immune response and application of the influenza B virus T1 peptide fragment, and belongs to the technical field of immunotherapy and immunodetection. Immunogenicity verification is carried out through ELISpot, T1 is detected to be positive in seven persons, the positive rate is 33.33%, S-T1 is detected to be positive in four persons, and the positive rate is 19.05%; the IFN-gamma secretory cells of the human PBMCs are detected through ELISpot, the immune response induced by the T1 in the HLA-A2 population can be up to 4160 SFC / 106 PBMC at most, and the S-T1 can be up to 990 SFC / 106 PBMC at most. Therefore, T1 and S-T1 can stably induce human T cells to generate immune response, can be used for monitoring the cellular immune level, can effectively activate the T cell immune response of people, and have the potential of being used as candidate vaccine epitope peptides to be applied to novel vaccine design.

Described herein is an engineered viral subunit vaccine encoding ASFV capsid proteins (e.g., P72 and Penton) for use in pigs. The vaccine with either P72 or Penton tested in mice elicited significantly higher levels of antigen-specific IgM and IgG, increased frequency of antibody-secreting cells in the bone marrow, and higher quality germinal centers in the spleens of immunized mice. Enhanced T cell responses were also observed, with higher levels of IFN-γ and TNF-α in splenocytes. Immunogenicity assessments in pigs further supported these findings, with both MB-P72 and MB-PN180Q inducing robust B cell and T cell responses. These findings show that expression of capsid proteins P72 and Penton in membrane-bound forms via mRNA preserves their native multimeric structure and enhances their immunogenicity and provides a basis for an effective ASFV vaccine.

Disclosed herein are an implantable therapeutic delivery system, methods of making the same, and methods of using the same. This system includes an electrochemical oxygen generator and a cell compartment comprising a semi-permeable nanofibrous membrane that is impermeable to cellular migration, an internal hydrogel matrix and one or more cells embedded in the hydrogel matrix. This system further includes a conduit in fluid communication between the electrochemical oxygen generator and the interior of the cell compartment, wherein the conduit delivers oxygen generated by the electrochemical oxygen generator to the one or more cells embedded in the hydrogel matrix.

The present application relates to a kind of monoclonal antibody that can identify human PSA antigen, secreting cell strain, its preparation method and its use in immunodetection.The above technical scheme selects the amino acid of 31-124 of PSA protein as antigen peptide, is codon optimized, becomes the gene fragment suitable for expression in escherichia coli BL21, and finally the recombinant protein includes TRX protein label, PSA protein fragment and histidine protein label.The recombinant protein is immunized to mouse, is fused by cell, screening and subcloning, obtains the mouse hybridoma cell strain 16F1 of high-efficiency secreted anti-PSA protein monoclonal antibody and the anti-PSA protein monoclonal antibody secreted by the cell strain.The antibody obtained in the present application has high specificity, sensitivity, and can specifically recognize the cell expressing PSA protein, is suitable for immunological detection, especially immunohistochemical detection.